Vivani Medical presents Phase 1 data showing no treatment-related adverse events with semaglutide implant
VANI•
VANI•Vivani Medical said none of 10 recipients of its NPM-139 semaglutide implant experienced treatment-related adverse events in a four-week Phase 1 study. The company plans a Phase 2 weight-maintenance trial in 2027, while five of 10 Wegovy recipients had treatment-related gastrointestinal events.
Vivani Medical reported no treatment-related adverse events among 10 recipients of its NPM-139 semaglutide implant in the four-week SLIM-1 study of 20 adults. Five of 10 Wegovy recipients had treatment-related gastrointestinal events, and no serious adverse events occurred in the study.
The company plans a Phase 2 dose-ranging weight-maintenance trial in 2027, targeting treatment for up to six months. NPM-139 is designed for once- or twice-yearly dosing; Novo Nordisk's evaluation remains ongoing.